Handling Pharmaceutical Market Complaints: GMP Guide

In short: A market complaint is any report that a marketed product may be defective. Every complaint must be recorded, assessed by Quality, investigated in proportion to risk, and closed with a documented decision, including whether other batches are affected or a recall is needed. This guide is for QA and QC staff and pharmacy students.

What is a market complaint?

A market complaint is any written or oral report from a customer, wholesaler, pharmacy, hospital, doctor or patient about the quality of a product after it has left the manufacturer’s control. Typical examples are broken or leaking packs, wrong or missing labels, foreign particles, discolouration, short counts, a suspected fake pack, or a suspected lack of effect.

Not every complaint is a quality defect. EU GMP Chapter 8 (§8.5, §8.7) expects every complaint to be documented and assessed to decide whether it is a potential quality defect. Complaints that are not (for example a suspected adverse reaction) are passed to the right function, such as pharmacovigilance, and still recorded.

What the regulations expect

Step-by-step handling

1. Receive and record

Record every complaint with all the original details (EU GMP §8.5, §8.10), for example who complained, product name and strength, batch number, nature of the complaint, date received, and the person who received it. 21 CFR 211.198(b)(1) lists the drug name and strength, lot number, complainant name, nature of the complaint and the reply to the complainant as record content where known. ICH Q7 §15.11 adds action taken with dates and the final decision on the batch.

2. Assess and classify

Quality assesses whether the complaint is a potential quality defect, an adverse event, or something else. Many sites classify by risk, for example critical (possible harm to patients), major, and minor. This is an example in-house criterion; the regulations ask for a risk-based approach (EU GMP §8.10, §8.13) but do not fix classes.

Pay special attention to whether the complaint relates to falsification or counterfeiting (EU GMP §8.6). A pack that does not look like genuine product may need urgent action.

3. Obtain the sample and check the facts

Request the complained sample or pack where possible and evaluate it (EU GMP §8.9). Check reference and retention samples and, where needed, the batch manufacturing record, batch certification record and distribution records, particularly for temperature-sensitive products.

4. Investigate and find the root cause

Apply an appropriate level of root cause analysis (§8.16). If the true root cause cannot be determined, identify and address the most likely cause. Where human error is suspected, justify it formally and make sure process or system causes are not overlooked (§8.17).

For a complaint about a possible failure to meet specification, 21 CFR 211.198(a) requires review by the quality control unit and a decision on whether an investigation is needed. If no investigation is made, 211.198(b)(3) requires the record to state why and name the responsible person who decided.

5. Check other batches

If a defect is found or suspected, consider other batches and, in some cases, other products. In particular, check batches that may contain portions of the defective batch or defective components, for example reprocessed material from it (EU GMP §8.11). Review earlier complaints for the same defect (§8.12).

6. Decide on risk-reducing action and recall

Decisions must match the level of risk and be timely, even when information is incomplete early in the investigation (§8.13, §8.14). Options range from no action, through a cautionary communication to healthcare professionals (§8.31), to a recall. Recall operations must be able to start promptly at any time, even before the root cause is known (§8.22).

7. Inform authorities and the marketing authorisation holder

Under EU GMP §8.15, quality defects that may lead to a recall or an abnormal restriction of supply are reported in a timely way to the marketing authorisation holder and all concerned competent authorities. Where a recall is planned, authorities should be informed in advance, although very serious issues may require action first (§8.26). For India, confirm the reporting route and timelines with your licensing authority and the applicable Schedule M requirements.

8. Reply to the complainant and close

Send a documented reply to the complainant, record the final decision on the batch, and document all decisions and measures taken (§8.14). Define and track CAPA and check its effectiveness (§8.18).

9. Review trends

Review complaint records regularly for specific or recurring problems (EU GMP §8.19; ICH Q7 §15.12). Trend by product, defect type, site and supplier, and use the review in the product quality review and management review.

Recalls in brief

A written, regularly reviewed recall procedure is required (§8.20). Any retrieval of marketed product because of a quality defect is managed as a recall (§8.21). Distribution records must be immediately available, with customer contact details and quantities (§8.23). Recalled product is segregated and stored securely until a documented decision on its fate (§8.28). Progress is recorded until closure, with a final report that reconciles delivered and recovered quantities (§8.29). The recall system’s effectiveness should be evaluated periodically, including out-of-hours, and mock recalls considered (§8.30).

Roles

• Complaint handler or Quality designee: trained, independent of sales and marketing, and responsible for investigation and measures (EU GMP §8.1). Where this person is not the Qualified Person or authorised person who released the batch, that person must be told formally and in time about investigations, risk-reducing actions and recalls.
• Quality Control: analyses the complained and retention samples.
• Production and Engineering: supply batch information and assist the investigation.
• Regulatory Affairs: communicates with authorities.

Record retention

Complaint records must be kept at least until 1 year after the expiry date of the respective product batch. 21 CFR 211.198(b) requires complaint records to be kept until at least 1 year after the product’s expiration date, or 1 year after the complaint was received, whichever is longer. For batch-related records generally, EU GMP Chapter 4 §4.11 requires retention for at least 1 year after expiry of the batch, or 5 years after QP certification if longer; 21 CFR 211.180(a) requires batch records to be kept at least 1 year after the batch’s expiration date. Keep records longer where local law or the marketing authorisation requires.

Frequently asked questions

Does every complaint need a full investigation? No. Depth should follow risk (EU GMP §8.10). But the decision not to investigate must be documented with the reason and the responsible person (21 CFR 211.198(b)(3)).

Who should handle complaints? Trained and experienced people who are independent of sales and marketing unless justified (EU GMP §8.1).

When must authorities be informed? In the EU, when a confirmed quality defect may result in a recall or abnormal supply restriction (§8.15). Check local rules for India and other markets.

Is a returned pack always a recall? No. Returning samples to help an investigation is not a recall (§8.21), but retrieving marketed product because of a defect is.

Related reading

• CAPA process: step-by-step instructions
• SOP on handling of incidents and deviations

References

1. European Commission, EudraLex Volume 4, EU GMP Guidelines, Part I Chapter 8: Complaints, Quality Defects and Product Recalls (revision in operation from 1 March 2015).
2. US eCFR, 21 CFR 211.198 Complaint files, and 21 CFR 211.180(a) General requirements for records (current text).
3. EU GMP Part I Chapter 4: Documentation, §4.11 (retention).
4. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Section 15 Complaints and Recalls (November 2000).